Scientific Sessions 2025  /  When the Left Heart Goes Bad: Pulmonary Hypertension Due to Left Heart Disease  /  Debate - Most Patients With CpcPH and RV Dysfunction Should Receive PAH-Targeted Therapies
Logo

American Heart Association

  37
  0

Final ID:

Debate - Most Patients With CpcPH and RV Dysfunction Should Receive PAH-Targeted Therapies

  • Thenappan, Thenappan  ( UNIVERSITY OF MINNESOTA , Eden Prairie , Minnesota , United States )
  • Ghio, Stefano  ( IRCCS POLICLINICO S.MATTEO , Pavia , Italy )
  • Forfia, Paul  ( Temple University Hospital , Philadelphia , Pennsylvania , United States )
    • Author Disclosures:
    Thenappan Thenappan: DO have relevant financial relationships ; Advisor:Merck:Past (completed) ; Researcher:Liquidia:Active (exists now) ; Researcher:Tenax:Active (exists now) ; Researcher:Merck:Active (exists now) ; Researcher:Aria CV:Active (exists now) ; Advisor:Aerovate:Past (completed) ; Advisor:GossemerBio:Past (completed) ; Advisor:Bayer:Past (completed) | STEFANO GHIO: No Answer | Paul Forfia: No Answer
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

When the Left Heart Goes Bad: Pulmonary Hypertension Due to Left Heart Disease

Monday, 11/10/2025 , 01:30PM - 02:45PM

Cardiovascular Seminar

More abstracts on this topic:
Beyond HFpEF: PH in Other Cardiomyopathies

Rosenkranz Stephan, Maron Brad, Simon Marc

Debate - Most Patients With CpcPH and RV Dysfunction Should NOT Receive PAH-Targeted Therapies

Maron Brad, Gomberg-maitland Mardi, Hemnes Anna, De Marco Teresa

More abstracts from these authors:
A Novel EMR-Based Algorithm with the Virtual Echocardiography Screening Tool (VEST) to Screen Patients for Pulmonary Arterial Hypertension

Narowska Gabriela, Anand Suneesh, Gangireddy Chethan, Enevoldsen John, Keane Martin, Edmundowicz Daniel, Forfia Paul, Vaidya Anjali

You have to be authorized to contact abstract author. Please, Login
Not Available